ARA-290
Also known as: Cibinetide
ARA-290 (Cibinetide) is a synthetic 11-amino-acid peptide derived from the helix-B surface of erythropoietin (EPO), developed by Araim Pharmaceuticals. It selectively activates the innate repair receptor (IRR) for anti-inflammatory, tissue-protective, and neuroprotective signaling without stimulating erythropoiesis. ARA-290 is not FDA-approved; it has received FDA Fast Track and Orphan Drug designations for sarcoidosis-associated small fiber neuropathy and remains in clinical development as of April 2026.
Who's worth your money for ARA-290
Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.
Top Merit pick
Highest Merit Score (99) of 17 scored sellers
$49.99 · 10mg · 100.0% purity
Best value after code
$3.09/mg effective with 10% code
$54.95 · 16mg · 99.0% purity
Most tested
8 independent COAs on file
$61.00 · 16mg · 99.6% purity
Average price
$6.13/mg
Sellers
47
45-day trend
-11%
33 of 47 sellers have a current price· 13 stale hidden· 3 unverified hidden
Top Merit pick
🇺🇸 Glacier Aminos99✓ verified at source · just now
$5.00/mg -18.5% vs avg$49.99
10mg
- 🇺🇸 BioLongevity Labs96
✓ verified at source · just now
$6.33/mg +3.2% vs avg$95.00
15mg
- 🇺🇸 Certified Peptides94
✓ verified at source · just now
$5.75/mg -6.3% vs avg$92.00
16mg
- 🇺🇸 Soma Peptides89
✓ verified at source · just now
$4.75/mg -22.6% vs avg$76.00
16mg
no purity - 🇺🇸 Peptide Plugs89
✓ verified at source · just now
$5.00/mg -18.5% vs avg$50.00
10mg
- 🇺🇸 Ruo Bio88
✓ verified at source · just now
$4.00/mg -34.8% vs avg$40.00
10mg
- 🇺🇸 Verified Peptides86
✓ verified at source · just now
$3.81/mg -37.9% vs avg$61.00
16mg
- optimasupply.is86
✓ verified at source · just now
$8.00/mg +30.4% vs avg$79.99
10mg
no purity - 🇺🇸 EZ Peptides85
✓ verified at source · just now
$4.80/mg -21.8% vs avg$48.00
10mg
- 🇺🇸 Alpha Omega84
✓ verified at source · just now
$7.60/mg +23.9% vs avg$76.00
10mg
Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.
Watch ARA-290
Get one email when the market actually moves — no newsletter, no noise.
About ARA-290
CAS
1208243-50-8
Molecular formula
C51H84N16O21
Sequence
UEQLERALNSS
Typical dose range
4 mg/day subcutaneous (clinical trial dosing for diabetic neuropathy and sarcoidosis-associated small fiber neuropathy)
Half-life
~20 minutes terminal half-life (after 4 mg SC injection; biological effect may persist 24–72 hours)
COAs for ARA-290
65 third-party tests across 23 vendors. Each card links to the full report.
For
Ara-290
by Hydro Research Peptides· batch HR-2026-1256
For
ARA-290
by Verified Peptides· batch ARA1026041D
For
ARA-290
by Longeva· batch B-2026-ARA-290-10-002
For
ARA-290
by Novaglo Research· batch 2001081226ARA
For
ARA-290
by OROS Research· batch OR-LPARA32-726-B2
For
ARA-290
by Novaglo Research· batch 11016672026AR
For
ARA-290
by Synthesis Peptides· batch ARA10826
For
ARA-290
by Ion Peptide· batch RA10-06172026
For
ARA-290
by Ion Peptide· batch RA10-06172026
For
ARA-290
by Ion Peptide· batch RA16-06242026
For
ARA-290
by Ion Peptide· batch RA16-06242026
For
ARA-290
by Real Peptides· batch BATCH-0322
For
ARA-290
by EZ Peptides· batch EZP-ARA1005192026-03
For
ARA-290
by OROS Research· batch OR-LPARA32-526-B1
For
ARA-290
by EZ Peptides· batch EZP-ARA1005192026-03
For
Ara-290
by Ion Peptide· batch ARA16-05202026
For
Ara-290
by Ion Peptide· batch ARA16-05202026
For
ARA-290
by Riptide Wellness· batch RWARA-10-1002
For
ARA-290
by Verified Peptides· batch ARA04260312C
For
ARA-290
by Verified Peptides· batch ARA0426031 2C
For
ARA-290
by Glacier Aminos· batch ARA10GA-01
For
ARA-290
by Peptide Crafters· batch PC-G1-AR16
For
ARA-290
by Peptide Supply Co.· batch AR1022026
For
ARA-290
by Modern Research Peptides· batch LCHK262
16 citations indexed for ARA-290
animal · 2026
Immunometabolic dysregulation drives selective executive cognitive dysfunction in male db/db mice
Type 2 diabetes (T2D) is associated with cognitive impairment, with executive functions such as cognitive flexibility being particularly vulnerable.
case-report · 2026
Case Report: Regenerative peptides for Inferior alveolar nerve injury: a narrative review with hypothesis-generating three clinical cases
Inferior alveolar nerve (IAN) injury represents a substantial complication in oral and maxillofacial surgery, often leading to persistent neurosensory dysregulation with limited effective treatment options.
animal · 2022
Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression
Alzheimer's disease (AD) pathology is characterized by amyloid-β (Aβ) deposition and tau hyper-phosphorylation, accompanied by a progressive cognitive decline. Monocytes have been recently shown to play a major role in modulating Aβ pathology, and thereby have been pointed as potential therapeutic targets.
animal · 2021
Synthesis and evaluation of <sup>99m</sup>Tc-DOTA-ARA-290 as potential SPECT tracer for targeting cardiac ischemic region
Objectives Myocardial infarction caused by ischemia of heart tissue is the main reason for death worldwide; therefore, early detection can reduce mortality and treatment costs.
animal · 2016
A Nonhematopoietic Erythropoietin Analogue, ARA 290, Inhibits Macrophage Activation and Prevents Damage to Transplanted Islets
Background Erythropoietin exerts anti-inflammatory, antiapoptotic, and cytoprotective effects in addition to its hematopoietic action. A nonhematopoietic erythropoietin analogue, ARA 290, has similar properties.
Study · 2016
ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: Integration between immune system and nociception
ARA 290 is an erythropoietin-derived polypeptide that possesses analgesic and tissue protective effect in many diseases such as diabetes and cancer.